Insulet Co. (NASDAQ:PODD) Stake Boosted by Shaker Investments LLC OH

Shaker Investments LLC OH raised its position in Insulet Co. (NASDAQ:PODD) by 83.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 20,234 shares of the medical instruments supplier’s stock after acquiring an additional 9,222 shares during the quarter. Insulet makes up 2.2% of Shaker Investments LLC OH’s portfolio, making the stock its 10th biggest holding. Shaker Investments LLC OH’s holdings in Insulet were worth $5,282,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of PODD. CWM LLC increased its stake in shares of Insulet by 3.4% in the 3rd quarter. CWM LLC now owns 3,984 shares of the medical instruments supplier’s stock worth $927,000 after purchasing an additional 132 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt raised its stake in shares of Insulet by 500.0% in the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 600 shares of the medical instruments supplier’s stock worth $139,000 after buying an additional 500 shares during the period. Exchange Traded Concepts LLC purchased a new position in shares of Insulet during the 3rd quarter valued at about $121,000. Swedbank AB grew its stake in shares of Insulet by 3.2% during the 3rd quarter. Swedbank AB now owns 21,232 shares of the medical instruments supplier’s stock valued at $4,942,000 after acquiring an additional 655 shares during the period. Finally, Cabot Wealth Management Inc. increased its holdings in Insulet by 1.7% in the 3rd quarter. Cabot Wealth Management Inc. now owns 15,983 shares of the medical instruments supplier’s stock worth $3,720,000 after acquiring an additional 262 shares in the last quarter.

Analyst Ratings Changes

PODD has been the topic of several analyst reports. Barclays lifted their price target on shares of Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. Raymond James upped their target price on shares of Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a report on Monday, October 14th. Canaccord Genuity Group raised their price target on Insulet from $269.00 to $304.00 and gave the company a “buy” rating in a report on Monday, December 9th. TD Cowen upped their price objective on Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a research note on Friday, January 3rd. Finally, BTIG Research lifted their target price on Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $277.13.

Insulet Trading Up 0.8 %

NASDAQ PODD opened at $285.34 on Tuesday. The stock has a market cap of $20.01 billion, a PE ratio of 48.86, a PEG ratio of 3.61 and a beta of 1.23. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $289.46. The company’s 50-day moving average price is $270.65 and its 200-day moving average price is $242.24. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21.

Insiders Place Their Bets

In other news, CAO Lauren Budden sold 915 shares of the business’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the sale, the chief accounting officer now owns 5,733 shares in the company, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the transaction, the executive vice president now owns 11,383 shares in the company, valued at approximately $3,187,240. This represents a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.47% of the company’s stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.